Opus Genetics, Inc. (Nasdaq: IRD) ('Opus Genetics” or the 'Company”), a clinical-stage biopharmaceutical company developing ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results